123 related articles for article (PubMed ID: 21449680)
1. Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.
Goertsches RH; Zettl UK; Hecker M
Pharmacogenomics; 2011 Mar; 12(3):423-32. PubMed ID: 21449680
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis.
Hong J; Zang YC; Hutton G; Rivera VM; Zhang JZ
J Neuroimmunol; 2004 Jul; 152(1-2):126-39. PubMed ID: 15223245
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.
Foti Cuzzola V; Palella E; Celi D; Barresi M; Giacoppo S; Bramanti P; Marino S
Pharmacogenomics J; 2012 Dec; 12(6):453-61. PubMed ID: 23044601
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment.
Lindberg RL; Kappos L
Expert Rev Mol Diagn; 2006 Nov; 6(6):843-55. PubMed ID: 17140371
[TBL] [Abstract][Full Text] [Related]
6. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
[TBL] [Abstract][Full Text] [Related]
7. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
Goertsches RH; Hecker M; Koczan D; Serrano-Fernandez P; Moeller S; Thiesen HJ; Zettl UK
Pharmacogenomics; 2010 Feb; 11(2):147-61. PubMed ID: 20136355
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of disease activity in multiple sclerosis.
Graber JJ; Dhib-Jalbut S
J Neurol Sci; 2011 Jun; 305(1-2):1-10. PubMed ID: 21463872
[TBL] [Abstract][Full Text] [Related]
9. Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
Tsareva EY; Kulakova OG; Boyko AN; Shchur SG; Lvovs D; Favorov AV; Gusev EI; Vandenbroeck K; Favorova OO
Pharmacogenomics; 2012 Jan; 13(1):43-53. PubMed ID: 22111603
[TBL] [Abstract][Full Text] [Related]
10. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
11. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis.
Serrano-Fernández P; Möller S; Goertsches R; Fiedler H; Koczan D; Thiesen HJ; Zettl UK
Autoimmunity; 2010 Mar; 43(2):172-8. PubMed ID: 19883335
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of interferon Beta therapy in multiple sclerosis.
Graber JJ; Dhib-Jalbut S
J Interferon Cytokine Res; 2014 Aug; 34(8):600-4. PubMed ID: 25084176
[TBL] [Abstract][Full Text] [Related]
13. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.
Stürzebecher S; Wandinger KP; Rosenwald A; Sathyamoorthy M; Tzou A; Mattar P; Frank JA; Staudt L; Martin R; McFarland HF
Brain; 2003 Jun; 126(Pt 6):1419-29. PubMed ID: 12764062
[TBL] [Abstract][Full Text] [Related]
14. [Interferon -beta therapy in multiple sclerosis].
Satoh J
Nihon Rinsho; 2006 Jul; 64(7):1297-309. PubMed ID: 16838648
[TBL] [Abstract][Full Text] [Related]
15. Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients.
Kulakova OG; Tsareva EY; Boyko AN; Shchur SG; Gusev EI; Lvovs D; Favorov AV; Vandenbroeck K; Favorova OO
Pharmacogenomics; 2012 Nov; 13(15):1689-700. PubMed ID: 23171334
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen.
Vandenbroeck K; Matute C
Pharmacogenomics; 2008 May; 9(5):639-45. PubMed ID: 18466107
[TBL] [Abstract][Full Text] [Related]
17. Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers.
Michałowska-Wender G; Losy J; Wender M; Januszkiewicz-Lewandowska D; Nowak J
Pol J Pharmacol; 2003; 55(5):877-80. PubMed ID: 14704481
[TBL] [Abstract][Full Text] [Related]
18. [Tailored therapy for multiple sclerosis].
Misawa T; Mizusawa H
Nihon Rinsho; 2008 Jun; 66(6):1135-9. PubMed ID: 18540359
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].
Tsareva EIu; Kulakova OG; Makarycheva OIu; Boĭko AN; Shchur SG; Lashch NIu; Popova NF; Gusev EI; Bashinskaia VV; L'vov DV; Favorov AV; Ochs MF; Favorova OO
Mol Biol (Mosk); 2011; 45(6):963-72. PubMed ID: 22295566
[TBL] [Abstract][Full Text] [Related]
20. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.
Weber F; Cepok S; Wolf C; Berthele A; Uhr M; Bettecken T; Buck D; Hartung HP; Holsboer F; Müller-Myhsok B; Hemmer B
Pharmacogenomics J; 2012 Jun; 12(3):238-45. PubMed ID: 21502966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
